Pharma patent litigation is often sold as a simple equation: legal bills in, settlement out.
But the real cost is usually bigger, slower, and harder to quantify—because the “bill” isn’t just what you pay your lawyers. It’s what you lose while you’re …

Australia’s “drug patent clock” sounds simple—until you look under the hood.
For years, the public conversation around drug pricing has treated patent protection like a single, fixed countdown: file the patent, wait the term, and then generics arrive. …

Pharma’s “reformulation playbook” is getting a lot of attention for a reason: it’s one of the few strategies that can simultaneously extend exclusivity, delay generic entry, and reset pricing power—often without the kind of breakthrough innovation pati…

Drug spend isn’t “inevitable.” It’s mismanaged. Here’s the procurement playbook that can cut it by 80%.
If you’re a hospital, health system, payer, or pharmacy leader, you already know the pain: drug costs rise faster than budgets, formularies lag real…

The Drug Patent Cliff Isn’t a “Legal” Problem—It’s a Procurement Problem.
If you manage sourcing, budgets, or supplier performance, you already know the uncomfortable truth: the next wave of generic and biosimilar competition won’t arrive with a memo. …

The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Can Imperil Sponsor Patents
Clinical development is already a high-wire act—timelines, trial execution, regulatory scrutiny, and data integrity. But there’s a quieter risk that’s sta…

Generic drug decisions in New Zealand aren’t just about science—they’re about timing, law, and a single hard deadline.
If you’ve ever watched a generic launch get delayed, you know the pattern: not one big surprise, but a chain of smaller ones—regulato…

Pharma’s “Patent Box” Is No Longer a Niche Tax Tweak—It’s Becoming a Board-Level IP Strategy
If you’re in life sciences, you’ve probably heard the phrase “patent box” tossed around like it’s just another tax optimization lever. But the reality is more …

180 Days: The Generic Launch Window That Can Make (or Break) Your Entire Year
In generic pharmaceuticals, timing isn’t just a schedule—it’s a strategy.
Ask anyone who’s lived through an ANDA launch cycle: the difference between a profitable, on-time ro…